Designing Resilient CDMO & Supply Chain Partnerships to Enable Rapid Scale-Up from Clinical to Pivotal for mRNA–LNP Therapies
9:00 am - Thursday 1st October 2026
- Moving beyond single-CDMO reliance by building flexible partnership models, including balancing primary and backup manufacturers without overextending budget or timelines. Driving early alignment with CDMOs on process characterization, PPQ strategy, batch sizing, and scale-up assumptions to minimize revalidation risk and accelerate pivotal readiness
- Strengthening supply chain resilience, including strategies for critical raw materials such as lipids and key components
- Establishing effective governance models to enable faster decision-making and seamless execution across partners
